Medicenna Therapeutics (TSE:MDNA) Reaches New 1-Year Low – Here’s Why

Medicenna Therapeutics Corp. (TSE:MDNA)’s stock price reached a new 52-week low on Tuesday . The stock traded as low as C$0.41 and last traded at C$0.41, with a volume of 65291 shares trading hands. The stock had previously closed at C$0.41.

Medicenna Therapeutics Stock Performance

The firm’s 50 day moving average is C$0.52 and its 200-day moving average is C$0.77. The stock has a market capitalization of C$33.79 million, a price-to-earnings ratio of -2.70 and a beta of 2.89. The company has a debt-to-equity ratio of 3.30, a quick ratio of 4.65 and a current ratio of 2.68.

Medicenna Therapeutics (TSE:MDNA) last released its quarterly earnings results on Thursday, April 30th. The company reported C($0.06) EPS for the quarter. Medicenna Therapeutics had a negative net margin of 533,640.00% and a negative return on equity of 103.51%. Analysts forecast that Medicenna Therapeutics Corp. will post -0.37 earnings per share for the current fiscal year.

About Medicenna Therapeutics

Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment. The have the potential to purge the tumor and un-blind the immune system to cancer thereby altering the treatment paradigm for a large majority of cancer patients.